Clinical Trial: The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07668076) titled 'The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients' on Sept. 17, 2023.

Brief Summary: the study aims to evaluate the cardioprotective effect of atorvastatin in breast cancer female patients treated with doxorubicin based chemotherapy

Study Start Date: Nov. 15, 2022

Study Type: INTERVENTIONAL

Condition: Breast Cancer Doxorubicin Induced Cardiomyopathy

Intervention: DRUG: Atorvastatin

atorvastatin 40 mg orally once daily for 3 months.

Recruitment Status: COMPLETED

Sponsor: Damanhour University

Published by HT Digital Content Services with permission from Health Daily Digest....